Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS)

Tipranks - Mon Apr 6, 12:02PM CDT

Analysts fell to the sidelines weighing in on Amgen (AMGN) and Airsculpt Technologies (AIRS) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Easter Sale - 70% Off TipRanks

Amgen (AMGN)

In a report issued on April 3, Courtney Breen from Bernstein maintained a Hold rating on Amgen. The company’s shares closed last Thursday at $347.94.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 19.4% and a 84.1% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $369.16, representing a 4.7% upside. In a report issued on April 2, Wells Fargo also assigned a Hold rating to the stock with a $390.00 price target.

See the top stocks recommended by analysts >>

Airsculpt Technologies (AIRS)

In a report issued on April 2, Sam Eiber from BTIG maintained a Hold rating on Airsculpt Technologies. The company’s shares closed last Thursday at $3.17, close to its 52-week low of $2.24.

According to TipRanks.com, Eiber is a 1-star analyst with an average return of -8.1% and a 18.2% success rate. Eiber covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Merit Medical Systems, and Apyx Medical. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Airsculpt Technologies.

Read More on AMGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.